Drugs Information:
Efalizumab
Basic Information
|
||
| ID | DDInter623 | |
| Drug Type | biotech | |
| Protein Chemical Formula | None | |
| Protein Average Weight | - | |
| CAS Number | 214745-43-4 | |
| Description | Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It was later withdrawn in 2009 due to a potential risk of progressive multifocal leukoencephalopathy (PML).[L43797] | |
| ATC Classification | L04AA21 | |
| Sequences | >Heavy Chain Variable Region EVQLVESGGGLVQPGGSLRLSCAASGYSFTGHWMNWVRQAPGKGLEWVGIMIHPSDSETR YNQKFKDIRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARIGIYFYGTTYFDYIWGQGTL VTVSS | |
| Useful Links | DrugBank PubChem Substance PharmGKB Therapeutic Targets Database Wikipedia ChEMBL | |
Interactions with
Efalizumab
Filter:
| Severity level | ID | Name | Mechanism | Detail |
|---|
Interactions with diseases
Filter:
| Severity level | Disease name | Text | References |
|---|
Interactions with foods
Filter:
| Severity level | Food name | Description | Management | Mechanism | References |
|---|
Interactions with compound preparation
| Multi-DRUG trade | Multi-DRUG | Drug type | Warning | Note |
|---|